Search results
Jul 16, 2024 · SOTIO Biotech is a company that develops immunotherapies for cancer patients. It has a pipeline of candidates based on immunocytokines, BOXR, and ADC platforms, and is conducting clinical trials in the U.S. and Europe.
- About us
The Company. SOTIO Biotech is shaping the future of cancer...
- Pipeline
SOTIO Biotech Inc. 180 Canal St., Suite 300 Boston, MA 02114...
- Clinical trials
Clinical Trials. Currently, SOTIO is conducting three...
- News & Publications
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO...
- IL-15 Superagonist
SOTIO Biotech a.s. Českomoravská 2532/19b 190 00 Prague 9...
- Antibody-Drug Conjugates
SOTIO also entered a license and option agreement with...
- Cell Therapies
SOTIO’s BOXR cell therapy platform is designed to improve...
- Science
SOTIO’s global team leverages its scientific excellence...
- About us
SOTIO's BOXR cell therapy platform is designed to improve functionality of engineered T cells by discovering novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment.
Oct 11, 2023 · SOTIO is developing SOT102, a Claudin 18.2 antibody-drug conjugate, for treatment of gastric and pancreatic cancers. The company announced the first patients dosed in combination arms of its Phase 1/2 CLAUDIO-01 trial.
Sotio is a biotechnology company that researches and develops innovative cancer treatments, including immunotherapy, antibody-drug conjugate, and cellular immunotherapy. It operates in Europe and the US, and has partnerships, licensing agreements, and acquisitions with other biotech companies.
Oct 11, 2023 · The SOTIO pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, nanrilkefusp alfa, currently being tested in Phase 2 clinical trials; SOT102, a next ...
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a next-generation PD-1-inhibiting cytokine, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
People also ask
What is Soto biotech?
What is Soto's clinical pipeline?
What is Sotio IL-15 superagonist?
What does Sotio do with Cytune Pharma?
SOTIO Biotech is a biotechnology research company based in Prague, Czech Republic, that develops new treatments for solid tumors. It has a robust clinical pipeline of immunocytokines, CAR T therapies and antibody-drug conjugates, and is a member of the PPF Group.
